Read more

Source: https://www.magnific.com/

Read more

Two approaches illustrate how such a rule might work.

Read more

That resilience earned its reward. Investors, unnerved by disruption, prized stability over growth, and companies obliged by hoarding cash, shoring up balance sheets and avoiding risk. A survey of American chief financial officers shows that concerns about trade and tariffs have fallen sharply since the second quarter of 2025, while worries about inflation, monetary policy and labour quality have risen — a return, in other words, to the “normal” anxieties of running a business.

That shift in mood is not merely psychological.

Read more

Read more

The company argues that its fortunes do not depend on whether a drug eventually secures regulatory approval. Instead, it generates revenue from the scientific work that supports a mole…

Read more

The overlap point is real and worth taking seriously. Index providers score constituents along a continuum of value-like and growth-like characteristics rather than assigning each company to a single camp, so a stock can draw weight in both benchmarks at once. The paper’s examples are well chosen: Alphabet, Amazon and Meta, conventionally filed under “growth,” now generate the kind of free cash flow and capital returns historically associated with value; Coca-Cola and American Express, filed under “value,” have produced growth-like earnings durability. That such firms can be the same business viewed through two lenses is a fair description of how index methodology actually works.

Where the paper is less convincing is in its leap from “the boundary is blurry” to “drift is therefore not really drift.” It frames style deviation as evidence of “process discipline rather than process breakdown,” but this is precisely the distinction any manager who has strayed from a mandate would want to draw. A value fund that increasingly holds stocks the market calls growth might indeed be following sound, repeatable logic -- or it might simply be chasing performance and redescribing the result as philosophy. The paper offers no external test for telling the two apart; it asks investors to trust the manager’s own account of its discipline.

The “Three Circle” framework -- valuation, fundamentals, momentum -- is a sensible enough description of how many active managers actually pick stocks, value-labelled or not. The “two-circle” watch list, holding pre-vetted names that satisfy two of three criteria and await the third, is a reasonable way to stay ready for dislocations. But it is also, structurally, a licence to hold growth-flavoured names on the basis that fundamentals and momentum are good enough, with valuation discipline promised as something that will eventually catch up. That is a defensible investment approach. It is a different thing from a finding that growth and value are not “mutually exclusive economic categories.”

None of this means Boston Partners’ process is poor; a 30-year record, cited in the paper, is at least suggestive that something in the approach works. But the paper is marketing material, explicitly labelled as such, written by a value house at a moment when growth stocks have dominated returns for years and rigid style boxes have arguably cost value managers assets. A philosophical case for flexibility is, among other things, a timely case for not being held to one.

Read more

Read more

Read more

In April 2025, large parts of Spain and Portugal suffered one of the most significant power disruptions in recent European history. For most observers, the event was a reminder of how fragile modern electricity grids can be.

Read more

At a time when antimicrobial resistance is emerging as one of the most serious threats to global healthcare, the company finds itself holding a portfolio of novel molecules that could potentially address infections that are becoming increasingly resistant to existing treatments. The debate today is no longer about whether Wockhardt can discover new drugs. Instead, the real question is whether it can successfully convert years of scientific achievement into a sustainable and profitable business.

From Generic Medicines to Drug Discovery

Like most successful Indian pharmaceutical companies, Wockhardt’s journey began with generic medicines. Over the years, however, the company steadily evolved beyond manufacturing and marketing pharmaceuticals.

Founded by Dr. Habil Khorakiwala, Wockhardt expanded into biotechnology, vaccines, insulin products and, most notably, novel antibiotic research. Today, the company operates manufacturing facilities across India, the United Kingdom and Ireland, maintains research centres in both India and the UK, and generates a significant share of its revenue from international markets.

By FY25, Wockhardt reported revenue of approximately ₹3,033 crore and EBITDA of ₹418 crore. Management described the organisation as a “global research-driven multinational” with businesses spanning pharmaceuticals, biotechnology and innovative anti-infective therapies.

What differentiates Wockhardt from many of its peers is its willingness to commit substantial capital and resources to original drug discovery. Even during periods marked by regulatory challenges, financial stress and weak profitability, the company continued investing in antibiotic research.

That persistence now sits at the heart of the investment thesis.

The Long Journey: A Decade of Challenges Before Recovery

The company’s journey over the last decade can broadly be divided into four distinct phases.

Phase I: Building a Global Pharmaceutical Business

Until the middle of the previous decade, Wockhardt resembled many successful Indian pharmaceutical exporters. It possessed a growing international presence, manufacturing facilities across multiple geographies, a strong branded pharmaceutical franchise and ambitious research programmes.

Behind the scenes, however, management was also building one of the world’s largest antibiotic discovery platforms outside the traditional pharmaceutical giants.

Phase II: Regulatory and Financial Stress

The period between FY2016 and FY2020 proved particularly challenging. USFDA observations affected key manufacturing facilities, profitability deteriorated sharply, debt levels increased and several years were marked by weak or negative earnings.

Despite these pressures, management chose to continue funding research programmes. At the time, many investors questioned whether the antibiotic pipeline would ever generate meaningful returns. Looking back, this was arguably the most difficult phase in the company’s modern history.

Phase III: Repairing the Balance Sheet

A major turning point came when Wockhardt sold a portfolio of domestic brands to Dr. Reddy’s Laboratories. The transaction helped reduce debt, strengthen liquidity, fund ongoing research and improve overall financial flexibility.

At the same time, management undertook a significant restructuring of the US business.

In February 2023, Dr. Murtaza Khorakiwala explained:

“Next slide, we have been mentioning over the last one year that the US business needs to get significantly restructured. And as it was having a significant amount of drain into the financial performance of the company, we have shut down our manufacturing facility at Morton Grove near Chicago and using a simple 80-20 formula, we have identified the product portfolio to be manufactured by a third party and that will be an ongoing continuing business that we will have. As a result of the entire restructuring of the manufacturing, we intend to save about $12 million in losses which we are currently incurring and however we will continue to maintain our sales in the US business as these products will be manufactured from a third party certified facility with approximately 40% gross margin”. —Dr. Murtaza Khorakiwala, Managing Director, Investor Call Transcript, 21 February 2023

The closure of the Morton Grove manufacturing facility and the shift towards outsourced production significantly improved profitability while allowing the company to maintain its presence in the US market.

Phase IV: Commercialisation Begins

The latest phase may prove to be the most important. Wockhardt’s focus has gradually shifted from drug discovery to commercialisation.

For the first time, investors can evaluate not only scientific progress but also the commercial opportunities emerging from the company’s research pipeline.

What Makes Wockhardt Different?

Wockhardt’s greatest strength does not lie in manufacturing, branding or even its global footprint. Instead, it lies in the antibiotic discovery platform that the company has spent nearly two decades building.

The company continued investing in solutions for antimicrobial resistance long after many global pharmaceutical companies reduced their focus on the area. That persistence has resulted in a portfolio that includes:

- ZAYNICH (WCK 5222)

- Nafithromycin (Miqnaf)

- WCK 6777

- WCK 4282

- Multiple other anti-infective assets

Beyond antibiotics, Wockhardt possesses several additional advantages.

Diversified Global Operations

The company derives a majority of its revenues from international markets and maintains meaningful positions in the UK and Ireland.

Biotechnology Platform

Its insulin and biosimilar businesses continue to provide diversification beyond traditional pharmaceuticals.

Improved Balance Sheet

Perhaps the most underappreciated achievement of recent years has been the improvement in financial health. Net debt-equity has declined significantly, reducing financial risk and improving strategic flexibility.

Source: Moneycontrol — https://www.moneycontrol.com/financials/wockhardt/ratiosVI/w05

Significant Intellectual Property

Decades of research have enabled the company to build a substantial intellectual property portfolio comprising thousands of patents. According to their website, “Till date, we have filed 3,037 patents cumulatively, and have been granted 628 patents.”

– https://www.wockhardt.com/about-us/research-and-development/ (10-Jun-2026)

Entering a New Phase of Growth

Unlike commodity businesses, pharmaceutical companies do not operate through traditional economic cycles. Instead, they move through product-development cycles.

Management commentary increasingly suggests that Wockhardt is transitioning from the discovery phase into the commercialisation phase of its innovation journey.

This distinction is important.

For most of the past two decades, the company’s future depended on scientific validation. Today, much of that science appears to have been validated. The next challenge is commercial execution.

Management has consistently indicated that the coming years will focus on regulatory approvals, product launches, physician adoption, international commercialisation and scaling revenues from novel antibiotics.

Risks Investors Should Not Ignore

Despite its strengths, Wockhardt remains a business with meaningful risks.

Commercialisation Risk

Scientific success does not automatically translate into commercial success. While the company has demonstrated its ability to discover drugs, it must now prove that it can build profitable global franchises around them.

Regulatory Risk

Like all pharmaceutical companies, Wockhardt remains exposed to inspections, approvals and evolving regulatory requirements. Its history demonstrates how significant regulatory setbacks can affect business performance.

Concentration Risk

A substantial portion of future value creation depends on a relatively small number of molecules. Any major setback in commercial launches could materially affect long-term outcomes.

Long Development Timelines

Drug discovery remains an inherently uncertain process, requiring patience and a willingness to accept timelines that are often much longer than those of conventional pharmaceutical businesses.

Management: Persistence as a Competitive Advantage

One of the strongest arguments in favour of management is consistency.

Many management teams alter their strategy when faced with setbacks. Wockhardt chose a different path. Despite regulatory issues, rising debt, weak profitability and investor scepticism, management continued funding its antibiotic programmes.

That persistence increasingly appears justified. The company’s debt reduction efforts, US restructuring and clinical progress indicate a management team capable of executing difficult long-term plans. At the same time, persistence can become a weakness if it limits strategic flexibility. The coming years will reveal whether management can be as effective at commercial execution as it has been at scientific development.

Succession: A Planned Transition

Historically, Wockhardt was closely associated with founder Dr. Habil Khorakiwala. Over time, greater responsibilities have been assumed by Dr. Murtaza Khorakiwala, Dr. Huzaifa Khorakiwala and Zahabiya Khorakiwala.

The transition appears deliberate rather than reactive. Investor presentations and annual reports increasingly feature second-generation leadership discussing operational and strategic priorities.

By 2026, Zahabiya Khorakiwala was directly involved in presenting the US strategy for ZAYNICH, suggesting that succession planning is already being executed rather than merely discussed.

Watchlist or Active Research Candidate?

A few years ago, Wockhardt was primarily viewed as a turnaround story. Today, the narrative appears different. Over the last several years, the company has reduced debt, improved profitability, advanced its research pipeline, demonstrated management execution, initiated leadership transition and moved closer to commercialising its innovation platform.

The central risk is no longer survival. The central question is monetisation.

For investors who maintain strict valuation discipline, Wockhardt increasingly appears worthy of active research rather than passive observation. Several important hurdles have already been crossed. The next hurdle, commercial success of its innovation platform, may prove to be the most consequential of all.

Conclusion

Most pharmaceutical companies spend their lives manufacturing medicines discovered by others. Wockhardt spent more than two decades attempting to discover its own.

That decision created years of financial strain, regulatory challenges and investor frustration. It also produced a portfolio of intellectual property that few Indian pharmaceutical companies possess.

After years of investing in research while repairing its balance sheet, Wockhardt appears to be approaching a pivotal phase in its evolution. The science appears increasingly validated, the balance sheet is considerably stronger and the next generation of leadership is steadily taking on greater responsibility.

What remains is commercial execution.

The next five years are likely to be decisive. If Wockhardt succeeds in commercialising its novel antibiotic portfolio, the company may ultimately be remembered not merely as another pharmaceutical manufacturer, but as one of the few Indian healthcare businesses that successfully built a globally relevant innovation platform from the ground up.

For different styles of investing, the read on this stock looks different.

Value Investor — There are two extreme views a value investor could take here. From a pure ratio perspective, the stock would likely be rejected outright, not even making it onto an active watchlist. A more contrarian value approach, however, might see this differently and consider it worth tracking.

Growth Investor — EPS growth has only just turned positive after ten years of decline. A growth-oriented investor would likely view this as early-stage and worth adding to a watchlist to track whether the trend holds.

Momentum Investor — Momentum investing is rules-based by design — the signal itself, not personal judgement, is what typically drives entry decisions for this style. Whether this stock fits depends entirely on the specific rules and indicators an individual momentum strategy uses.

Disclaimer

This article is prepared solely for informational and educational purposes and should not be construed as investment advice, research advice, a recommendation, solicitation or an offer to buy or sell any security. Readers should conduct independent due diligence and seek advice from a registered financial adviser, tax adviser, accountant or other qualified professional before making investment decisions. Past performance, management commentary and industry trends do not guarantee future results.

Food for thought:

There are many ways to build a position, and different investing styles tend to approach it differently. Value and growth investors often build positions gradually, in multiple tranches, rather than all at once — a practice that spreads entry-price risk over time. Momentum-oriented approaches tend to use smaller position sizes per stock, reflecting the higher turnover and risk typically associated with that style.

What’s “right” depends entirely on an individual’s risk appetite, time horizon, and overall portfolio construction — none of which can be assessed from a single article. This is exactly the kind of decision worth discussing with a SEBI-registered Investment Adviser, who can assess your specific situation before any position sizing approach is applied.

Hexagon Nutrition has spent more than three decades doing precisely that.

Founded in 1993, the company began life as a micronutrient formulations business. Over time it expanded into clinical nutrition, wellness products, therapeutic foods and international nutrition programmes. Today, it positions itself as a research-oriented nutrition company with operations across more than 70 countries and manufacturing facilities in India and Uzbekistan.

What distinguishes Hexagon is not merely the breadth of its product portfolio but its attempt to control multiple layers of the nutrition ecosystem, from formulation and manufacturing to public-health nutrition and branded clinical products.

Source: www.magnific.com

Yet as the company approaches its stock market debut, investors face a more nuanced question. The story is no longer only about nutrition. It is increasingly about succession, capital allocation and whether a scientifically capable manufacturer can successfully transform itself into a recognised nutrition brand.

From Premixes to Branded Nutrition

At its core, Hexagon manufactures micronutrient premixes—customised blends of vitamins, minerals and nutritional ingredients supplied to food companies and nutrition brands. These premixes are used in food fortification initiatives, healthcare products and consumer nutrition applications.

Read more

Read more

Read more

Read more

Read more

An a recent interview, Dorsey offers a timely reassessment. His arguments challenge several widely held assumptions, particularly around metrics, management quality, and the durability of competitive advantage.

What is a moat, really?

Dorsey defines a moat simply: a structural feature that makes a business hard to compete with and allows it to exercise pricing power. These features vary by industry. Consumer brands rely on brand equity; enterprise software often depends on switching costs; platforms may benefit from network effects.

The nuance lies in sustainability. A strong product is not the same as a moat. Investors often conflate the two. A product may be popular today but easily replicable tomorrow. The real test is whether a company can maintain demand and pricing power over time.

This distinction aligns with broader academic and practitioner thinking. Research from institutions like Harvard Business School has long emphasised that competitive advantage must be both valuable and difficult to imitate to persist.

The limits of traditional metrics

One of Dorsey’s sharper critiques is directed at the over-reliance on quantitative metrics such as return on invested capital (ROIC). Historically, sustained high returns signalled a moat. Today, that signal is weaker.

The reason is structural. Many modern businesses, especially software and internet firms, derive value from intangible assets like code, data, and networks. These do not sit neatly on balance sheets. As a result, traditional accounting understates invested capital and inflates returns.

This concern is echoed in research by McKinsey & Company, which has highlighted how intangible-heavy firms distort conventional financial ratios. In such cases, qualitative assessment becomes more important than mechanical screening.

Moats are not all “inevitable”

A common misconception is that a moat implies permanence. Dorsey rejects this. He distinguishes between “inevitable” moats, slow-changing businesses like consumer staples, and more dynamic moats in sectors such as semiconductors or software.

The latter may be less stable but offer greater reinvestment opportunities due to faster industry growth. The trade-off is clear: stability versus growth. Investors must decide which suits their strategy.

The experience of companies like PayPal illustrates the risk. Once seen as a strong network-effect business, it lost ground as payment ecosystems evolved and competitors like Apple and Google integrated payments more seamlessly into their platforms. The moat did not disappear overnight; it eroded as the value delivered by the network declined.

Network effects: overestimated and misunderstood

Network effects are often treated as the gold standard of moats. Dorsey urges caution. Not all networks are equal, and their durability depends on the value they provide.

A large user base alone is insufficient. If alternative platforms offer better functionality or integration, users can migrate. The lesson isstraightforward: a moat must be evaluated in terms of user benefit, not just scale.

This perspective is consistent with work by Geoffrey Parker, who notes that network effects can weaken if multi-homing, users engaging with multiple platforms, becomes easy.

Management: the overlooked variable

Beyond business economics, Dorsey places heavy emphasis on management quality. The traits he values are not glamorous: humility, openness to dissent, and disciplined capital allocation.

He is particularly wary of founder-led firms. While founders can be visionary builders, they do not always transition well into managers of large organisations. Micromanagement, which may help in early stages, becomes a constraint at scale.

This view contrasts with the market’s tendency to idolise founders. Evidence suggests a more mixed reality. Studies by Stanford Graduate School of Business indicate that founder-led firms outperform in some contexts but underperform when governance and capital allocation weaken.

Pricing power and its limits

Pricing power is often cited as proof of a moat. Dorsey adds an important caveat: price increases must be accompanied by value creation.

If companies simply extract higher prices without reinvesting in the product, the moat weakens over time. What appears as strength can become a “melting ice cube”.

This aligns with the broader concept of customer surplus in economics. Firms that consistently deliver value retain loyalty; those that exploit it invite disruption.

Process over prediction

Dorsey’s investment process avoids rigid screens. Instead, he focuses on narrowing the universe to industries where moats are more likely, such as software, semiconductors, and aerospace, while largely ignoring areas like commodities or highly competitive financial services.

He also advocates for a “premortem” approach: assume an investment fails and work backwards to identify why. This helps distinguish signal from noise and sharpens decision-making.

Perhaps most striking is his emphasis on behavioural edge. In a world where information is widely available, the advantage lies less in knowing more and more in thinking differently, and patiently.

The bottom line

The idea of economic moats remains relevant, but its application requires adaptation. Traditional metrics are less reliable, network effects are not foolproof, and management quality can make or break even the strongest business model.

The implication for investors is clear: analysis must move beyond checklists. It requires judgement, scepticism, and a willingness to revise assumptions as industries evolve.

In that sense, the moat is not a static feature of a business. It is a dynamic one, built, tested, and sometimes eroded over time.

Read more

Read more